REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
PR Newswire —
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026 Robust patient enrollment continues in confirmatory trial Surabgene lomparvovec...